1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sunesis Pharmaceuticals, Inc. - Strategy and SWOT Report

Sunesis Pharmaceuticals, Inc. - Strategy and SWOT Report

  • December 2015
  • -
  • MarketLine
  • -
  • 23 pages

Summary

Table of Contents

Search Inside

Introduction

Sunesis Pharmaceuticals, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Sunesis Pharmaceuticals, Inc. required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Sunesis Pharmaceuticals, Inc. in the form of a SWOT analysis

- An in-depth view of the business model of Sunesis Pharmaceuticals, Inc. including a breakdown and examination of key business segments

- Intelligence on Sunesis Pharmaceuticals, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Sunesis Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Sunesis Pharmaceuticals (Sunesis or 'the company') is a development-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company operates in the US. It is headquartered in South San Francisco, California, and employed 39 people as on December 31, 2014. The company recorded revenues of $5.7 million during the financial year ended December 2014 (FY2014), a decrease of 27.9% compared with FY2013. The operating loss of the company was $45 million in FY2014, as compared with an operating loss of $31.8 million in FY2013. The net loss of the company was $43 million in FY2014, as compared with a net loss of $34.6 million in FY2013.

Reasons to Purchase:

- Gain understanding of Sunesis Pharmaceuticals, Inc. and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Sunesis Pharmaceuticals, Inc. as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Sunesis Pharmaceuticals, Inc.’s business structure, strategy and prospects

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Mild Cognitive Impairment - Pipeline Review, H1 2017

Mild Cognitive Impairment - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • April 2017
  • by Global Markets Direct

Mild Cognitive Impairment - Pipeline Review, H1 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2017, ...

Gastric Ulcers - Pipeline Review, H1 2017

Gastric Ulcers - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • April 2017
  • by Global Markets Direct

Gastric Ulcers - Pipeline Review, H1 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H1 2017, provides an overview of ...

Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017

Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • March 2017
  • by Global Markets Direct

Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) – Pipeline Review, ...

Autism - Pipeline Review, H1 2017

February 2017 $ 2000

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.